Opinion|Videos|December 16, 2025
Exploring Potential Implications of CHOPIN Trial Data in Metastatic Uveal Melanoma
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), discuss the potential clinical implications of the CHOPIN trial in metastatic uveal melanoma.
Advertisement
Episodes in this series
Prof.Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), explore the clinical implications of data from the phase 2 CHOPIN trial (NCT04283890) and how the findings may influence treatment sequencing or combination strategies in metastatic uveal melanoma. They discuss how improved hepatic control may translate into meaningful survival outcomes and potentially reshape management algorithms. Forschner and Khan explain which patient populations may be best suited for this combined liver-directed and immunotherapy approach.
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
The combination nearly doubled the confirmed response rate in the randomized phase 2 portion of HexAgon-HN, with the greatest benefit in HPV-positive disease.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
The 2026 amendment adds 40 new recommendations, including active surveillance, office-based treatment, and chemoablation for select recurrent low-grade disease.
The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
By finding a way to attack the most important human oncogene, KRAS, the UCSF chemical biologist launched a new era in cancer treatment.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
Advertisement
Advertisement
Trending on OncLive
1
INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC
2
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
3
The OncFive: Top Oncology Articles for the Week of 9/27/2026
4
NDA Submission Is Initiated for Zipalertinib Plus Chemotherapy in Frontline EGFR Exon 20 Insertion+ NSCLC
5